Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637623 · ClinicalTrials.gov registry record · Phase 2
Study of Cardiovascular Disease and Obstructive Sleep Apnea
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01637623 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 87 participants.
The verdict
NCT01637623, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if two medicines (allopurinol and losartan) can influence heart and blood vessel health compared to placebo in patients with sleep apnea who are using continuous positive airway pressure (CPAP).
Interventions
- DRUG Placebo
- DRUG Losartan
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01637623
The ClinicalTrials.gov registry entry for NCT01637623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01637623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01637623 about?
NCT01637623 is a clinical study titled "Study of Cardiovascular Disease and Obstructive Sleep Apnea". The purpose of this study is to determine if two medicines (allopurinol and losartan) can influence heart and blood vessel health compared to placebo in patients with sleep apnea who are using continuous positive airway pressure (CPAP).
What is the current status of trial NCT01637623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2012-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01637623?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT01637623?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.